SOUTH SAN FRANCISCO, Calif. / Apr 22, 2024 / Business Wire / Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the Pediatric Endocrine Society (PES) 2024 Annual Meeting taking place May 2-5, 2024, in Chicago, IL.
In the poster presentation, Paul Thornton, M.B.B.S., will highlight baseline characteristics from Spruce’s CAHmelia program evaluating tildacerfont in adult congenital adrenal hyperplasia (CAH), as an illustration of outcomes of current pediatric CAH disease management.
PES 2024 Presentation Details:
Title: Baseline Characteristics of Two Randomized, Placebo-controlled Trials with Tildacerfont in Adults (CAHmelia Studies) Highlight Unmet Medical Need in Pediatric Congenital Adrenal Hyperplasia
Abstract Number: 6898
Poster Session: 2
Session Date & Time: Friday, May 3, 2024: 12:15 – 1:45 p.m. CT
Presenter: Paul Thornton, M.B.B.S., Principal Investigator and Medical Director of the Endocrine and Diabetes Program at a CAH Center of Excellence
The poster will be available on the company’s website beginning May 3, 2024 at 12:15 p.m. CT. Access more information about PES 2024 here.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal, once-daily therapy for patients suffering from classic congenital adrenal hyperplasia (CAH) and other endocrine disorders. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook, and YouTube.
| Last Trade: | US$135.29 |
| Daily Change: | 5.37 4.13 |
| Daily Volume: | 28,185 |
| Market Cap: | US$76.230M |
December 10, 2024 November 11, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
